Becton, Dickinson and Company Acquires Edwards Lifesciences' Critical Care Business for $4.2 Billion

In a strategic move to expand its medical monitoring solutions, Becton, Dickinson and Company (BD) has announced the acquisition of Edwards Lifesciences' critical care business for $4.2 billion in cash. The acquired business is a global leader in advanced patient monitoring solutions, focusing on innovative hemodynamic monitoring technologies.

The critical care business, with around 4,500 employees primarily based in Irvine, California, generated over $900 million in revenue in 2023. Its product portfolio includes the gold-standard Swan-Ganz pulmonary artery catheters, minimally invasive sensors, noninvasive cuffs, tissue oximetry sensors, and monitors. Leveraging advanced data analytics, machine learning, and AI-based predictive algorithms, the business aims to provide clinicians with a more comprehensive understanding of a patient's current and future condition, as well as decision support tools.

According to the transaction terms, the acquisition is expected to immediately enhance BD's key financial metrics, including earnings growth, adjusted gross margin, adjusted operating margin, and adjusted earnings per share. The critical care business is projected to deliver sustained earnings growth of 6-7%, with an initial adjusted gross margin of at least 60% and an adjusted operating margin of at least 25%, which is expected to improve over time.

The acquisition aligns with BD's BD2025 strategy, as strategic and value-creating mergers and acquisitions remain a key component of the company's financial framework. Modest synergies are anticipated, primarily from sales costs, supply chain efficiencies, and lower general and administrative expenses through the implementation of BD's operating excellence system, while preserving the commercial operations and innovation capabilities of the critical care business.

To fund the acquisition, BD plans to utilize approximately $1 billion in cash and $3.2 billion in new debt. Upon completion of the transaction, expected by the end of this year, BD's pro forma net leverage ratio is anticipated to be around 3x, which the company expects to reduce to its long-term target of 2.5x within 12 to 18 months, primarily through free cash flow generation.

The critical care business will operate as a separate business unit within BD's medical segment, aligned with the company's smart connected care strategy, and will maintain its headquarters in Irvine, California. The transaction is subject to customary regulatory approvals and closing conditions.